Biotech Values

[BioSpecialist]

Undiscovered Stock....Allergy Vaccine Successful in PIII


Allergy Therapeutics (AGY.L)

Marktkap: 29 million GBP ( 57,5 million US$ )
Cash: 8 million GBP ( 15,8 million US$ )
Kurs: 35 p

Pipeline:
http://www.allergytherapeutics.com/uploads/pipeline2.jpg


The vaccine that could cure hay fever forever
By JENNY HOPE - More by this author »
Last updated at 02:22am on 15th May 2008
http://www.dailymail.co.uk/news/article-566513/The-vaccine-cure-hay-fever-forever.html


15 May 2008
Allergy Therapeutics Pollinex Quattro Phase III trial meets efficacy goal UPDATE

LONDON (Thomson Financial) - Allergy Therapeutics plc (LSE: AGY.L - news) (Advertisement)
, the specialist pharmaceutical company focused on allergy vaccination, today announces positive results from its Pollinex Quattro Grass Phase III study, G301, the largest controlled allergy vaccine study ever conducted, it said.

The result clears the way for the company to apply for marketing approval in the European Union, with the submission planned for the first quarter of next year.

The company currently has development in the US on hold while the FDA has a clinical stay in place.

Keith Carter, chief executive officer of Allergy Therapeutics, said this is the most important piece of news in the 70-year history of the company.

He told Thomson Financial News in a telephone interview: 'We've invested very hard, this is why we went public to fund these trials and it's really great to be able to announce that it's all been worthwhile. Clearly this is a huge step forward not just for us but for allergen vaccination generally and for patients who suffer from allergies.'

He added that the trial also showed that Pollinex Quattro had a good safety profile and patients complied well with the dosing requirement.

Marketing director Kevin Wilkinson estimated that the market in Europe for allergy vaccines was about 500 million euro.

The announcement is expected to boost current sales of Pollinex Quattro, which are on a named-patient basis, as well as boost future sales after registration.

Carter explained that the announcement would help the company in licensing talks. 'We would like to partner to accelerate the introduction of the product across Europe and these results will allow us to have very meaningful conversations with partners,' he said.

Nomura Code Securities, in a note to clients, said it viewed the results as 'highly encouraging'.

'We view these results as highly encouraging for out-licensing prospects and EU approval. We continue to believe that the FDA clinical hold will be lifted and reiterate our 'Buy' recommendation with a price target of 118p, based only on approval and sales in the EU.'

At 10.16 am shares were up 26.96 percent, or 7.75 pence, to 36.5 pence/share, bringing the market capitalisation up to 24 million pounds.


Presentation March 2008
http://www.allergytherapeutics.com/uploads/InterimResultsPresentationMarch08Final.pdf

More Info
http://www.iii.co.uk/investment/detail?code=cotn:AGY.L&display=news&it=le